Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 8.42
(3.69%)
CNY 8.42
(3.69%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.19 Billion CNY | 14.72% |
| 2022 | 2.78 Billion CNY | 45.83% |
| 2021 | 1.9 Billion CNY | -8.41% |
| 2020 | 2.08 Billion CNY | 0.12% |
| 2019 | 2.08 Billion CNY | 12.59% |
| 2018 | 1.84 Billion CNY | 80.28% |
| 2017 | 1.02 Billion CNY | 10.72% |
| 2016 | 925.7 Million CNY | 5.89% |
| 2015 | 874.18 Million CNY | 53.63% |
| 2014 | 569.02 Million CNY | 14.49% |
| 2013 | 497.02 Million CNY | 40.97% |
| 2012 | 352.57 Million CNY | 20.44% |
| 2011 | 292.72 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 2.66 Billion CNY | -9.19% |
| 2024 Q1 | 3.15 Billion CNY | -1.12% |
| 2024 Q2 | 2.93 Billion CNY | -6.95% |
| 2023 FY | 3.19 Billion CNY | 14.72% |
| 2023 Q2 | 2.94 Billion CNY | -2.36% |
| 2023 Q3 | 3.21 Billion CNY | 9.17% |
| 2023 Q4 | 3.19 Billion CNY | -0.71% |
| 2023 Q1 | 3.01 Billion CNY | 8.39% |
| 2022 Q1 | 2.12 Billion CNY | 11.13% |
| 2022 Q2 | 2.53 Billion CNY | 19.63% |
| 2022 Q4 | 2.78 Billion CNY | 1.7% |
| 2022 Q3 | 2.73 Billion CNY | 7.86% |
| 2022 FY | 2.78 Billion CNY | 45.83% |
| 2021 FY | 1.9 Billion CNY | -8.41% |
| 2021 Q1 | 1.96 Billion CNY | -5.89% |
| 2021 Q2 | 1.9 Billion CNY | -2.93% |
| 2021 Q3 | 1.99 Billion CNY | 4.62% |
| 2021 Q4 | 1.9 Billion CNY | -4.17% |
| 2020 Q1 | 2.15 Billion CNY | 3.54% |
| 2020 FY | 2.08 Billion CNY | 0.12% |
| 2020 Q2 | 2.24 Billion CNY | 4.14% |
| 2020 Q4 | 2.08 Billion CNY | -0.92% |
| 2020 Q3 | 2.1 Billion CNY | -6.29% |
| 2019 Q2 | 1.89 Billion CNY | -2.68% |
| 2019 Q1 | 1.94 Billion CNY | 5.15% |
| 2019 FY | 2.08 Billion CNY | 12.59% |
| 2019 Q4 | 2.08 Billion CNY | 1.73% |
| 2019 Q3 | 2.04 Billion CNY | 8.15% |
| 2018 Q1 | 1.09 Billion CNY | 6.64% |
| 2018 FY | 1.84 Billion CNY | 80.28% |
| 2018 Q4 | 1.84 Billion CNY | 81.12% |
| 2018 Q3 | 1.02 Billion CNY | -0.38% |
| 2018 Q2 | 1.02 Billion CNY | -6.3% |
| 2017 FY | 1.02 Billion CNY | 10.72% |
| 2017 Q1 | 971.7 Million CNY | 4.97% |
| 2017 Q2 | 1.08 Billion CNY | 11.74% |
| 2017 Q3 | 1.05 Billion CNY | -3.04% |
| 2017 Q4 | 1.02 Billion CNY | -2.64% |
| 2016 Q3 | 892.7 Million CNY | -0.35% |
| 2016 Q1 | 940.38 Million CNY | 7.57% |
| 2016 Q2 | 895.8 Million CNY | -4.74% |
| 2016 Q4 | 925.7 Million CNY | 3.7% |
| 2016 FY | 925.7 Million CNY | 5.89% |
| 2015 Q1 | - CNY | -100.0% |
| 2015 FY | 874.18 Million CNY | 53.63% |
| 2015 Q3 | 831.16 Million CNY | 0.0% |
| 2015 Q4 | 874.18 Million CNY | 5.18% |
| 2014 Q4 | 489.02 Million CNY | 0.0% |
| 2014 FY | 569.02 Million CNY | 14.49% |
| 2013 FY | 497.02 Million CNY | 40.97% |
| 2012 FY | 352.57 Million CNY | 20.44% |
| 2011 FY | 292.72 Million CNY | 0.0% |